Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

  • I. Lang - , National Institute of Oncology (Author)
  • C. H. Koehne - , Klinikum Oldenburg - University Medicine (Author)
  • G. Folprecht - , Department of Internal Medicine I, TUD Dresden University of Technology (Author)
  • M. P. Nowacki - , Maria Sklodowska-Curie Institute of Oncology (Author)
  • S. Cascinu - , Marche Polytechnic University (Author)
  • I. Shchepotin - , Zaporizhia Medical Academy of Post-Gradate Education Ministry of Health of Ukraine (Author)
  • J. Maurel - , University of Barcelona (Author)
  • D. Cunningham - , Royal Marsden NHS Foundation Trust (Author)
  • A. Zubel - , Merck KGaA (Author)
  • E. Van Cutsem - , KU Leuven (Author)

Details

Original languageEnglish
Pages (from-to)345-345
Number of pages1
JournalEuropean Journal of Cancer : EJC Supplements
Volume7
Issue number2
Publication statusPublished - Sept 2009
Peer-reviewedYes

Conference

Title15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology
Duration20 - 24 September 2009
CityBerlin
CountryGermany

External IDs

ORCID /0000-0002-9321-9911/work/142252023

Keywords

Sustainable Development Goals